AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors
Open Access
- 1 January 2020
- journal article
- Published by Fortune Journals in Journal of Cancer Science and Clinical Therapeutics
- Vol. 4 (4), 511-525
- https://doi.org/10.26502/jcsct.5079091
Abstract
Dysregulation of the receptor tyrosine kinase AXL is known to promote cancer cell growth and survival in many sarcomas, including the rare subtype, malignant peripheral nerve sheath tumors (MPNST). MPNSTs are largely chemoresistant and carry a poor prognosis. AXL is an attractive potential therapeutic target, as it is aberrantly expressed, and its activation may be an early event in MPNST. However, the effect of AXL inhibition on MPNST development and progression is not known. Here, we investigated the role of AXL in MPNST development and the effects of AXL and MEK1/2 co-inhibition on MPNSTs. We used western blotting to examine AXL expression and activation in MPNST cell lines. We analyzed the effects of exogenous growth arrest-specific 6 (GAS6) expression on downstream signaling and the proliferation, migration, and invasion of MPNST cells. The effect of AXL knockdown with or without mitogen-activated protein kinase (MAPK) inhibition on downstream signal transduction and tumorigenesis was also examined in vivo and in vitro. We found that AXL knockdown increased MAPK pathway signaling. This compensation, in turn, abrogated the antitumorigenic effects linked to AXL knockdown in vivo. AXL knockdown, combined with pharmacological MEK inhibition, reduced the proliferation and increased the apoptosis of MPNST cells both in vitro and in vivo. The pharmacological co-inhibition of AXL and MEK1/2 reduced MPNST volumes. Together these findings suggest that AXL inhibition enhances the sensitivity of MPNST to other small molecule inhibitors. We conclude that combination therapy with AXL inhibitor may be a therapeutic option for MPNST.Keywords
This publication has 51 references indexed in Scilit:
- AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.BMC Cancer, 2015
- Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutationsOncogene, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Expression of ‘drugable’ tyrosine kinase receptors in malignant peripheral nerve sheath tumour: potential molecular therapeutic targets for a chemoresistant cancerHistopathology, 2011
- TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human CancerAdvances in Cancer Research, 2008
- Malignant Peripheral Nerve Sheath TumorThe American Journal of Surgical Pathology, 2003
- Receptor tyrosine kinases as targets for anticancer drugsTrends in Molecular Medicine, 2002
- Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumorsVirchows Archiv A Pathological Anatomy and Histopathology, 2001
- Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosisCell, 1992
- Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 casesCancer, 1990